Cabio Biotech Wuhan Co Ltd (688089) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.034x

Based on the latest financial reports, Cabio Biotech Wuhan Co Ltd (688089) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥56.10 Million ≈ $8.21 Million USD) by net assets (CN¥1.64 Billion ≈ $239.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Cabio Biotech Wuhan Co Ltd to measure how many days the company can operate on defensive assets alone.

Cabio Biotech Wuhan Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Cabio Biotech Wuhan Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Cabio Biotech Wuhan Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cabio Biotech Wuhan Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Marine Products Corporation NYSE:MPX	0.077x
Satin Creditcare Network Limited NSE:SATIN	0.255x
Dah San Electric Wire & Cable Co Ltd TW:1615	0.047x
Sky Harbour Group Corp NYSE MKT:SKYH	-0.012x
Anton Oilfield Services Group F:5AO	0.045x
Ser Educacional Sa SA:SEER3	0.073x
Jouder Precision Industry Kunshan Co Ltd SHE:300549	0.044x
Globus Spirits Limited NSE:GLOBUSSPR	0.246x

Annual Cash Flow Conversion Efficiency for Cabio Biotech Wuhan Co Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Cabio Biotech Wuhan Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Cabio Biotech Wuhan Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	CN¥1.57 Billion ≈ $229.67 Million	CN¥173.04 Million ≈ $25.32 Million	0.110x	+139.09%
2023-12-31	CN¥1.49 Billion ≈ $218.60 Million	CN¥68.89 Million ≈ $10.08 Million	0.046x	-62.75%
2022-12-31	CN¥1.43 Billion ≈ $208.53 Million	CN¥176.40 Million ≈ $25.81 Million	0.124x	+65.60%
2021-12-31	CN¥1.38 Billion ≈ $202.20 Million	CN¥103.29 Million ≈ $15.11 Million	0.075x	-32.18%
2020-12-31	CN¥1.32 Billion ≈ $193.67 Million	CN¥145.88 Million ≈ $21.35 Million	0.110x	+4.38%
2019-12-31	CN¥1.25 Billion ≈ $182.85 Million	CN¥131.95 Million ≈ $19.31 Million	0.106x	-47.66%
2018-12-31	CN¥526.20 Million ≈ $77.00 Million	CN¥106.16 Million ≈ $15.53 Million	0.202x	-6.93%
2017-12-31	CN¥464.39 Million ≈ $67.96 Million	CN¥100.66 Million ≈ $14.73 Million	0.217x	+39.56%
2016-12-31	CN¥402.60 Million ≈ $58.91 Million	CN¥62.53 Million ≈ $9.15 Million	0.155x	+23.62%
2015-12-31	CN¥354.83 Million ≈ $51.92 Million	CN¥44.58 Million ≈ $6.52 Million	0.126x	+26.32%
2014-12-31	CN¥465.90 Million ≈ $68.18 Million	CN¥46.34 Million ≈ $6.78 Million	0.099x	+7.89%
2013-12-31	CN¥428.24 Million ≈ $62.66 Million	CN¥39.48 Million ≈ $5.78 Million	0.092x	--

About Cabio Biotech Wuhan Co Ltd

SHG:688089 China Biotechnology

Market Cap

$280.03 Million

CN¥1.91 Billion CNY

Market Cap Rank

#15250 Global

#4494 in China

Share Price

CN¥11.37

Change (1 day)

-0.96%

52-Week Range

CN¥11.37 - CN¥29.99

All Time High

CN¥48.06